These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 7776946)
1. Toward allocative efficiency in the prescription drug industry. Guell RC; Fischbaum M Milbank Q; 1995; 73(2):213-30. PubMed ID: 7776946 [TBL] [Abstract][Full Text] [Related]
2. Haggling for a patent: what a government would have to pay for prescription drug patents. Guell RC Health Econ; 1997; 6(2):179-85. PubMed ID: 9158969 [TBL] [Abstract][Full Text] [Related]
4. The Affordable Prescription Drugs Act: a solution for today's high prescription drug prices. Pinzone JD J Law Health; 2001-2002; 16(1):145-68. PubMed ID: 14650775 [No Abstract] [Full Text] [Related]
5. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
6. Should the patent system for new medicines be abolished? DiMasi JA; Grabowski HG Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100 [No Abstract] [Full Text] [Related]
8. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
9. Balancing innovation, access, and profits--market exclusivity for biologics. Engelberg AB; Kesselheim AS; Avorn J N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525 [No Abstract] [Full Text] [Related]
10. Patents: a threat to innovation? Manocaran M Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557 [No Abstract] [Full Text] [Related]
11. Lowering the cost of prescription drugs. Jindal B J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276 [No Abstract] [Full Text] [Related]
12. Drug patent protection: how long is long enough? Sibbald B CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146 [No Abstract] [Full Text] [Related]
13. Reach-through claims for drug target patents: Rx for pharmaceutical policy. Bohrer RA Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015 [No Abstract] [Full Text] [Related]
14. Deadweight loss of bacterial resistance due to overtreatment. Elbasha EH Health Econ; 2003 Feb; 12(2):125-38. PubMed ID: 12563660 [TBL] [Abstract][Full Text] [Related]
15. Prescription drug pricing: the consumer perspective. Searing A N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625 [No Abstract] [Full Text] [Related]
16. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
17. Pharmaceuticals, patents, and politics: Canada and Bill C-22. Lexchin J Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783 [TBL] [Abstract][Full Text] [Related]
18. Life, death, and monopoly rights in a democratic society. Smith SJ Am J Bioeth; 2002; 2(3):43-4. PubMed ID: 12230856 [No Abstract] [Full Text] [Related]